Share
Services
Fresenius Digital Technology Polska sp. z o.o., with its registered office in Wrocław (address: pl. Nowy Targ 28, 50-141 Wrocław), entered into the Register of Entrepreneurs of the National Court Register maintained by the District Court for Wrocław-Fabryczna in Wrocław, 6th Commercial Division of the National Court Register under KRS number 0000914913, NIP 8943171759, with a share capital of PLN 135,000.00, is represented by the Management Board acting in accordance with the rules of representation disclosed in the National Court Register.
We are committed to maintaining the highest standards of ethics and integrity. In accordance with Polish regulations, individuals can confidentially report any suspected violations, unethical behavior or compliance issues through the following channels:
Email: sygnalisci@fresenius.com
Group Whistleblowing Channel: Our grievance mechanism | FSE
All reports are handled with strict confidentiality and in line with applicable data protection laws. Retaliation against whistleblowers is strictly prohibited.
Fresenius has published the Aide Memoire ahead of its Q2 2025 financial reporting. The Aide Memoire is a summary of relevant information that Fresenius has previously communicated previously to the capital market or otherwise made publicly available . The document may prove helpful in assessing Fresenius' financial performance ahead of the publication of quarterly results.
The Q2 2025 Aide Memoire is now available on the Fresenius Investor Relations website. The results of the second quarter and first half of 2025 of Fresenius SE & Co. KGaA will be published on 6 August 2025. The Quiet Period will start on 24 July 2025.
Worldwide
This year marks a major milestone in our company’s history: the 50th anniversary of Fresubin®. What began as a clinical solution in 1975 has grown into a trusted and comprehensive enteral nutrition product brand for patients around the world.
Worldwide
With Scribe, our Quirónsalud hospitals are revolutionizing the Spanish healthcare system. The Ai-powered application enhances efficiency and quality while also strengthening the doctor–patient relationship – for more humanity in medicine.
Worldwide
"While adapting to climate change is managed at a local level, we have set global emission reduction targets that help us to meet related expectations and to coordinate our efforts."
Germany
Our Sustainability Advisory Board got together for the first meeting of this year at Fresenius Kabi’s production and logistics site in Friedberg.
Worldwide
They serve patients beyond expectations and always give their best – not just in the fight against cancer, but also when striving for the highest possible quality of life.
Worldwide
"In our view, sustainability management represents a real opportunity and is essential for securing the resilience, competitiveness, and long-term success of companies."
Germany
Professor Dr. Michael Untch from Helios Hospital Berlin-Buch explains how the new antibody-drug conjugates (ADCs) are changing the fight against cancer.
USA
Read our interview with Chris Wegener, to find out more about the device development for CAR-T cell therapy at Fresenius Kabi.
Germany
How Fresenius Kabi is revolutionizing the treatment of cancer patients with the help of the Lovo and Cue cell processing systems.
Germany
Helios Hospital Berlin-Buch is one of the first hospitals in Germany to use augmented reality in the operating room.
Europe
By supporting the renowned museum foundation, the healthcare company demonstrates its social responsibility. The partnership is at the same time a clear commitment to Frankfurt and the Rhine-Main region.
Germany
Read our interview to find out what Dr. Anna Ossami Saidy, a doctor in training at the Helios Clinic Berlin-Buch, is currently researching.
Deutschland
#FutureFresenius is making the company fit for the future. And the brand identity must reflect and support this.
Germany
How artificial intelligence helps to detect polyps that can’t be seen by the human eye
Germany
“Personalized tumor medicine can be more effective at fighting tumors and produce beneficial therapies with fewer side effects.”
Germany
Get to know more about how this year started for Michael Sen, his view on trends like AI in health care and health equity.
Germany
Hendrik Otto and Verena Kaiser from Helios explain the benefits of changing your diet
Europe
Quirónsalud focuses on digitalisation to improve oncology patient care
Germany
Interview with Prof. Iwasaki, winner of the Else Kröner Fresenius Prize for Medical Research 2023, endowed with 2.5 million euros.
Germany
Anesthetic gas recycling reduces greenhouse gas emissions by 90 percent
Latin America
Fresenius Kabi Employees in the Dominican Republic are working to create a healthier environment.
Europe
Dr. Veronika Wolter is the first deaf person in Germany to achieve the position of chief physician. She herself uses a hearing prosthesis, and understands her patients very well.
Europe
Fresenius Helios uses the latest robotic technology to make surgery gentler for patients – for example at Helios Hospital Erfurt in Germany.
Europe
How two brave adventurers from Switzerland are exploring the world step-by-step.
Europe
As a leading global healthcare group we are dedicated to medicine and human health - values we have upheld since our founding as a pharmacy lab in 1912.
Nutrition is a topic that surrounds us every day. While we often talk about obesity and weight loss diets, we actually overlook that the opposite, meaning malnutrition or undernutrition, can be as detrimental. We speak of malnutrition when the body is not provided with enough nutrients, such as protein, carbohydrates, fats, vitamins, and minerals, which are essential for maintaining all vital body functions.
When our nutritional status is not optimal, the body becomes less resilient in facing challenges like illness, colds, or infections. Improving our nutritional status will therefore support and protect our body.
This year marks the 50th anniversary of Fresubin®, Fresenius Kabi’s trusted enteral nutrition brand. Since 1975, Fresubin® has supported over 300 million people in more than 75 countries, helping patients with their dietary management and therefore connection to life when everyday nourishment becomes a challenge.
From chronic disease and critical illness to aging, cancer care, and rehabilitation, Fresubin® has played a vital role in restoring nutritional support. Because when eating becomes difficult or impossible, nutrition is no longer just fuel. It becomes a foundation of patients’ life.
Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.
This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.
Conexxence®(1) and Bomyntra®(2) are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.
Read the full press release here.
Fresenius announced today that its Operating Company Fresenius Kabi has introduced two new biosimilars in the U.S., Conexxence®(1) (denosumab-bnht) and Bomyntra®(2) (denosumab-bnht).
These denosumab biosimilars are approved by the FDA for all indications of the reference products, Prolia®(3) (denosumab) and Xgeva®(4) (denosumab), respectively. The biological medicines are used for the treatment of osteoporosis and other bone-related conditions.
This milestone represents Fresenius’ fifth and sixth biosimilars available in the U.S. It is a showcase of the company’s efforts to drive patient access to high-quality biological medicines. Earlier this year, Fresenius announced a global settlement with Amgen concerning its denosumab biosimilars. The company thereby continues the growth path of its BioPharma platform in line with #FutureFresenius.
Conexxence®(1) and Bomyntra®(2) are registered trademarks of Fresenius Kabi Deutschland GmbH in selected countries. Prolia®(3) and Xgeva®(4) are registered trademarks of Amgen Inc.
Read the full press release here.
July 22, 2025
virtual
Fresenius Sustainability Highlights Magazin 2024
